Ownership and insider activity for Tango Therapeutics, Inc. (TNGX): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions.
Price
| Price | $22.72 (closing price, October 30, 2026) |
| Market Cap | $3.8B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-01 | Crystal Adam | M-Exempt | 27,000 | $140K |
| 2026-10-01 | Crystal Adam | M-Exempt | 27,000 | $140K |
| 2026-10-01 | Crystal Adam | S-Sale | 26,400 | $646K |
| 2026-10-01 | Crystal Adam | S-Sale | 600 | $15K |
| 2026-09-22 | Newcomb Jessica | S-Sale | 700 | $16K |
| 2026-09-22 | Newcomb Jessica | S-Sale | 5,100 | $122K |
| 2026-09-22 | Newcomb Jessica | S-Sale | 2,400 | $60K |
| 2026-09-01 | Crystal Adam | M-Exempt | 27,000 | $140K |
| 2026-09-01 | Crystal Adam | M-Exempt | 27,000 | $140K |
| 2026-09-01 | Crystal Adam | S-Sale | 27,000 | $604K |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $22.9M | $28.4M | $142.7M | $60.0M | $66.4M | $69.5M | $112.3M |
| Short-term Investments | $17.5M | $161.9M | $342.5M | $306.2M | $270.5M | $188.4M | $230.9M |
| Receivables | 0 | $2.0M | $2.0M | $2.0M | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $41.7M | $193.6M | $492.3M | $375.3M | $346.5M | $266.3M | $353.8M |
| Property, Plant & Equipment | $11.8M | $11.3M | $6.1M | $57.8M | $53.4M | $47.6M | $42.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $55.8M | $207.3M | $500.2M | $436.5M | $402.6M | $316.5M | $398.7M |
| Accounts Payable | $670,000 | $1.8M | $3.2M | $4.5M | $2.8M | $1.6M | $1.2M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $25.9M | $40.9M | $40.7M | $55.5M | $45.9M | $38.2M | $21.7M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | $30.8M |
| Total Liabilities | $47.9M | $168.7M | $155.4M | $187.0M | $149.5M | $117.0M | $52.5M |
| Retained Earnings | -$51.1M | -$103.1M | -$161.3M | -$269.5M | -$371.3M | -$501.6M | -$603.2M |
| Total Equity | $7.9M | $38.6M | $344.7M | $249.5M | $253.1M | $199.5M | $346.2M |
| Total Debt | $8.5M | $7.9M | $1.5M | $41.1M | $38.9M | $36.5M | $33.6M |
| Net Debt | -$31.9M | -$182.4M | -$483.8M | -$325.0M | -$298.0M | -$221.4M | -$309.6M |
| Working Capital | $15.8M | $152.7M | $451.6M | $319.7M | $300.6M | $228.2M | $332.1M |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 50.82 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 9.88 |
Profitability
| Return on Equity | -25.74% |
| Return on Invested Capital | -12.90% |
| Return on Assets | -11.52% |
| Gross Margin | 98.25% |
| Operating Margin | -253.38% |
| Net Margin | -229.92% |
Related companies: RVMD · ERAS · IDYA · RLAY · NRIX
Explore sector: Healthcare · Biotechnology
More sections of TNGX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks